Impact of thyroid autoimmunity on cumulative delivery rates in in vitro fertilization/intracytoplasmic sperm injection patients
Many studies have been reported that investigate and improve success rates after in in vitro fertilization. Thyroid autoimmunity may be an important factor determining fertility treatment outcome.
David Unuane, M.D., Brigitte Velkeniers, M.D., Ph.D., Sander Deridder, M.S., Bert Bravenboer, M.D., Ph.D., Herman Tournaye, M.D., Ph.D., Michael De Brucker, M.D., Ph.D.
To predict the impact of thyroid autoimmunity (TAI) on the probability of delivery after a defined number of treatment cycles, using analysis of cumulative delivery rates in patients with and without TAI.
Retrospective cohort study performed at the Center for Reproductive Medicine and Department of Endocrinology, University Hospital of Brussels, approved by the institutional review board of the hospital.
All patients who started their first IVF/intracytoplasmic sperm injection cycle at our fertility center between January 1, 2010 and December 31, 2011 were included.
Main Outcome Measure(s)
Live birth delivery after 25 weeks’ gestation was taken as the primary endpoint of our study Cumulative delivery rates were calculated for both groups until six treatment cycles.
All patients (in both groups) received the usual IVF treatment protocols (i.e., antagonist or agonist protocol).
In total 2,406 women who consulted our center were included. We included 333 patients with TAI and 2019 patients without TAI. In the TAI group the crude cumulative delivery rate after six cycles was 47%, whereas the expected cumulative delivery rate was 65%. In our control the crude cumulative delivery rate after six cycles was 47%, whereas the expected cumulative delivery rate was 76%.
Our study did not confirm an influence of TAI status in patients undergoing fertility treatment on cumulative delivery rates after six IVF/intracytoplasmic sperm injection cycles.
Read the full text at: http://www.fertstert.org/article/S0015-0282(16)300...